Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Pozycja w akcjach #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Cena akcji
$0.28545656
Kapitalizacja rynkowa
$4.50M
Zmiana (1 dzień)
5.97%
Zmiana (1 rok)
0.00%
Kraj
FR
Handel Acticor Biotech SAS (ALACT)

Kategoria

Wskaźnik P/B dla Acticor Biotech SAS (ALACT)
Wskaźnik P/B na dzień March 2026 TTM: -0.57
Według najnowszych raportów finansowych i ceny akcji Acticor Biotech SAS, obecny wskaźnik P/B (TTM) wynosi -0.57. Na koniec 2022 wynosił -33.19.
Historia wskaźnika P/B dla Acticor Biotech SAS od 2010 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
5.6573 -1,096.18%
DK
6.3842 -1,224.18%
US
2.4551 -532.31%
US
4.364 -868.45%
BE
2.5504 -549.09%
AU